In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. 
Introduction
Melanoma is the most dangerous type of skin cancers owing to its high metastatic potential and resistance to therapeutic agents (1, 2). Melanoma cells are derived by malignant transformation of melanocytes that produce melanin to protect the skin cells against ultraviolet (UV) damage. In normal skins, UV stimulates keratinocytes to secret growth factors, such as stem-cell factor, fibroblast growth factor, and hepatocyte growth factor. These factors stimulate melanocytes for melanin production as well as for proliferation and differentiation. However, melanocytes undergo malignant transformation in the individuals who either have a genetic defect in melanin production, i.e. albinism, or are intermittently exposed to intense UV light. In the early stages, the melanocytes grow and form benign naevi near the epidermis-dermis junction. As the disease progresses, the melanoma cells grow radially and then vertically at later stage showing growth pattern of pagetoid spread. The vertical growth of melanoma leads to metastatic malignancy, whereby melanoma cells infiltrate into blood vessels and lymphatic system. Melanoma diagnosed at early stage is usually cured by a local surgical excision; however, metastatic malignant melanoma has a poor prognosis even after surgery. Therefore, it is necessary to develop a therapeutic agent to treat the late stages of melanoma, especially targeting metastatic dispersion.
The intense UV radiation can damage genomic DNAs directly by formation of thymine dimer adduct or indirectly by intracellular production of reactive oxygen species (ROS). Indeed, melanoma involves various genetic mutations in the oncogenes and tumor suppressors (3). malignancy of melanoma cells. An important consideration is that these gene products are linked to cellular redox homoestasis. For example, the Ras activation has been known to induce robust production of cellular ROS (4, 5). The lipid phosphatase activity of PTEN was regulated by reversible oxidation of the active site cysteine residue (6, 7). Recently, Jenkins et al showed that p16 INK4a regulates the cellular ROS level in skin cell types including keratinocytes and melanocytes (8). Furthermore, the NADPH oxidases, which produce superoxide anion by transferring an electron to molecular oxygen, have been shown to influence melanoma cell cycle and growth (9, 10). Although the involvement of ROS in melanoma formation and metastasis was proposed (11), the endogenous antioxidant enzyme has not been studied in relation to melanoma pathophysiology.
Mammalian cells have well-defined endogenous antioxidant enzymes that include superoxide dismutases, catalase, glutathione peroxidases, and peroxiredoxins. Among these enzymes, peroxiredoxin (Prx) is the most abundant and known to be involved in receptor tyrosine kinase-mediated signal transduction (12). Interestingly, it has recently been shown that one of the Prx family members Prx2 (gene loci, Prdx2), which belongs to 2-cys Prx subfamily and reduces the peroxides in the presence of NADPH by coupling with thioredoxin/thioredoxin reductase system, is down-regulated in melanoma cell lines and particularly metastatic malignant types (13, 14) . However, the function of the Prx2 enzyme in the melanoma cell growth and metastasis remains unknown.
In this study, we investigated the role of the Prx2 peroxidase in in vitro cellular function and in vivo metastasis of melanoma cells. The level of Prx2 expression inversely correlated with in vitro proliferatory and migratory activities and in vivo metastatic potential of melanoma cells. We also elucidated a novel Prx2-mediated signaling pathway for suppression of melanoma metastasis, which involves a synergistic collaboration of the ERK-dependent E-
Materials and Methods
Reagents, RNAi, and cell culture U0126 was purchased from Cell Signaling Technology. PD98059, PP2 and PP3 were from Calbiochem. Gliotoxin (GT) was from Sigma-Aldrich. Zonula adherens sampler kit was kindly provided by BD Transduction Laboratories 
Immunoblot analysis
The cells were rinsed once with ice-cold phosphate-buffered saline (PBS) and then lysed in an extraction buffer containing 20 mM Hepes (pH 7.0), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 2 mM EGTA, 1 mM DTT, 5 mM Na 3 VO 4 , 5 mM NaF, 1 mM AEBSF, aprotinin (5 μg/ml), and leupeptin (5 μg/ml). After centrifugation at 12,000×g, the clarified cell extract was used for immunoblotting. To control for loading, the membranes were stripped by shaking them for 30 mins at 60°C in 67 mM Tris (pH 6.7), 2% SDS, 100 mM 2-mercaptoethanol and re-probed with the appropriate pan antibody.
Immunocytochemistry
The cells were grown on glass cover slides and fixed with pre-warmed 4% paraformaldehyde solution for 15 mins. The fixed cells were washed twice with PBS and permeabilized with 0.2% Triton X-100 for 30 mins at room temperature. After permeabilization, the cells were then blocked with 2% BSA in PBS (blocking buffer) for 1 hr and incubated at 4 °C overnight with the indicated primary antibodies diluted in a blocking buffer: anti-phosphotyrosine 
Retrovirus production
The retroviruses encoding human Prx2 were generated using a bicitronic pLXIN vector and a Retro-X Q vector system (Clontech). First, the coding sequence for human Prx2 wild-type (WT) was inserted by PCR cloning into pLXIN. The resulting vector was used for viral production by stably transfecting a NIH3T3-based dualtropic packaging cell line RetroPack TM PT67. These viruses were mainly used for the Prx2 overexpression in the SK-MEL cells. Second, the production of retrovirus encoding my-tagged human Prx2 WT and inactive CS mutant (Cys51Ser/Cys173Ser) using the Retro-X Q vector system was previously described (16). The viral titers were determined (1 x 10 6 viral particles/ml) and the aliquots were stored at 70 °C. For retroviral infection, the viral aliquots were thawed in warm water bath and mixed with 10 μg/ml polybrene.
Proliferation and migration assays
The cell proliferation was measured using a WST-1 cell proliferation assay kit (Roche were added to the inserts, which contained retrovirus or transfection complex. After 24 hrs, the infected or transfected melanoma cells were serum-starved for 18 hrs. Solutions of 20%
FBS were then added to the bottom chambers with basal media with 0.5% BSA. The upper chamber wells were filled with each basal media containing 0.5% BSA. Transwell chambers were incubated at 37°C/5% CO 2 for 12 hrs. After incubation, the non-migrated cells were removed from the top of the filters. The cells that migrated onto the bottom of filters were fixed and stained with 0.6% hematoxylin and 0.5% eosin. The stained cells were photographed and counted. The number of migrating cells was averaged from triplicate wells.
Wound closure assay
A wound was made on the monolayer of cells by scratching with a pipette tip. The cells were then washed with PBS to removed cell debris and fed with fresh culture medium. Cells were allowed to proliferate and migrate into the wound during the next 12 hrs. Migration of cells into the wound was observed using a microscope. The wound width was measured using Image J software.
Protein tyrosine phosphatase assay
The control or Prx2 WT retrovirus-infected SK-MEL-28 ( To test the effect of gliotoxin, the C57/BL6 mice were intraperitoneally injected with gliotoxin (300 μg/kg) five times during the 10 days following an intravenous injection of melanoma cells.
Statistics
Data were analyzed using Student's t test on SigmaPlot 8.0 software, and the P value was derived to assess statistical significance. A P < 0.02 was considered to be significant.
Results

Prx2 suppresses melanoma cell proliferation and migration
We immunoscreened the melanoma cell lines using the Prx2-specific antibody for level of Fig. 2C and D) . Subsequently, we performed the specific knockdown of the Prx2 expression using two different small-interfering RNAs (siRNA) in G361 and A375 cells (Fig. 3A) . The Prx2 knockdown significantly increased cell proliferation and migration in both cells responding to the serum stimulation ( Fig. 3B and C).
In contrast, the knockdown of another cytosolic Prx isoform, Prx1, did not affect the melanoma cell activities (Fig. 3D) . Collectively, the results indicate that the Prx2 enzyme functions as a selective antioxidant suppressor for proliferation and migration of melanoma cells.
Prx2 negatively regulates c-Src and ERK activation in a H 2 O 2 -dependent manner
To elucidate the molecular mechanism by which Prx2 controls melanoma function, we examined the serum-induced protein phosphorylation in SK28 cells. The serum stimulation induced tyrosine phosphorylation in a timely manner, which was lowered by the Prx2 expression ( (Fig. 4C ). Since the PTPs exhibit broad substrate specificity, we then dissected downstream signaling pathways important for melanoma biology. In particular, the Ras-Raf-MEK-ERK and PI3K-Akt pathways are critical for melanoma cell proliferation, survival, and migration (2). In addition, the Src kinase, which is highly activated in various cancers (19) , has also been proven to be involved in melanoma progression (20, 21) . Therefore, we examined the serum-dependent activation of c-Src kinase, ERK, and Akt in SK28 melanoma cells. As a result, the c-Src and ERK activation, but not the Akt activation, were markedly attenuated by the Prx2 expression (Fig. 4D) . The specific knockdown of Prx2, but not Prx1, in G361 cells inversely increased the c-Src and ERK activation in response to serum (Fig. 4E ). Subsequently, we tested whether the activation of these two kinases is sufficient for controlling melanoma cell function. The inhibition of ERK activation was achieved by a selective MEK inhibitor PD98059, while the Src inhibition was achieved by a reversible ATP-competitive inhibitor PP2. PD98059 and PP2 were titrated out to determine the optimum inhibitory concentrations in the SK28 cells. The results indicated that the inhibition of each of MEK/ERK and Src kinases sufficiently blocked melanoma cell proliferation and migration ( Fig. 4F and G) .
Next, we addressed whether the peroxidase activity of the Prx2 is required for melanoma cell function. To this end, we expressed the human Prx2 WT and its inactive mutant (CS), where the two active-site cysteine residues, Cys51 and Cys172, are mutated to serine residues, in SK28 cells by retroviral transduction (Supplementary Fig. S2A ). The Prx2 WT eliminated the basal and serum-induced H 2 O 2 levels, whereas the CS mutant did not (Supplementary Fig. S2C and D) . Together, the results indicate that the peroxidase activity of the Prx2 is essential for eliminating intracellular H 2 O 2 and regulating melanoma cell function.
Prx2 increases the E-cadherin/β-catenin complexes in adherens juctions
The invasion and metastasis of the tumor cells directly involves the epithelial-mesenchymal transition (EMT) (22) . In particular, loss of E-cadherin-catenin complexes in adherens junctions is a critical step for acquiring metastatic ability. Therefore, to understand the molecular mechanism underlying the Prx2-dependent mobilization of melanoma cells, we examined the level of adherens junctional proteins in melanoma cells after the Prx2 reexpression or depletion. The SK28 cells expressed various types of cadherins and catenins ( Supplementary Fig. S3 ). Among various junctional proteins, the Prx2 expression did not affect the levels of the catenin proteins but evidently increased the E-cadherin expression in SK-MEL cells ( Fig. 5A and B) . Inversely, the Prx2 knockdown in G361 cells decreased the E-cadherin expression (Fig. 5B) . To further seek a connection between Prx2 and catenins, we tested whether Prx2 possibly influences the subcellular distribution of catenin proteins. Surprisingly, the Prx2 expression increased the β-catenin levels in the plasma membrane, particularly in adherens junction as indicated by co-localization with E-cadherin (Fig. 5C ).
The quantification of the fluorescence intensity along a straight line indicated that the β-catenin moved from cytosol to the plasma membrane. Conversely, the Prx2 knockdown in G361 cells reduced the β-catenin levels in the plasma membrane (Fig. 5D ). In addition, the immunostaining data confirmed that the E-cadherin expression was proportional to the Prx2 expression. To delineate the signaling mechanism underlying the Prx2-dependent reorganization of the adherens junctions in melanoma cells, we explored whether the Src/ERK, which had been down-regulated by Prx2, plays a key role in the formation of E-cadherin/β-catenin complexes.
It has been reported that the Src phosphorylates β-catenin on tyrosine 654 (Y654), which triggers the release of β-catenin from the adherens junction (23, 24) . Indeed, the Src inhibitor PP2, but not the BRAF/MEK inhibitors, blocked the serum-induced Y654 phosphorylation of β-catenin in SK28 cells (Supplementary Fig. S4A ) and then resulted in a marked increase of β-catenin level in the plasma membrane of melanoma cells (Supplementary Fig. S4B ).
Subsequently, we found that the Prx2 re-expression in SK28 cells appreciably inhibited the serum-induced Y654 phosphorylation of β-catenin compared to that in control cells (Fig. 5E ), whereas its knockdown in G361 cells increased the β-catenin phosphorylation (Fig. 5F) . Thus, the results indicate that the Prx2 induced membrane retention of β-catenin by inhibiting the Src-dependent Y645 phosphorylation. Unexpectedly, we observed that the Src inhibition also increased the E-cadherin level, which might be due in part to the role of Src in the deregulation of E-cadherin by endocytosis (25). Moreover, it was shown that the ERK activation triggers the EMT via inhibiting the E-cadherin expression (26, 27) . Indeed, the blockade of ERK and Src pathways using two independent MEK inhibitors (PD98059 and U0126) and PP2, respectively, both increased the E-cadherin level in SK28 cells (Supplementary Fig. S4C ). Conclusively, the data demonstrate that the ERK and Src pathways were independently involved in the Prx2-mediated augmentation of the Ecadherin/β-catenin complexes.
Absence of Prx2 enhances lung metastasis of melanoma cells
Based on the regulatory activity of Prx2 in proliferation and migration of melanoma cells, we 
performed an in vivo experiment using a lung metastasis model of mouse melanoma cells, B16F10. Since the B16F10 cells are known to express wild-type BRAF (28), we examined whether the Prx2 still regulates the Src/ERK pathways and cellular activity of B16F10 cells.
The Prx2 knockdown using mouse Prx2-specific siRNAs increased the Src/ERK activation and the β-catenin phosphorylation, while it decreased the E-cadherin level in B16F10 cells (Fig. 6A) . Consistently, the Prx2 knockdown increased proliferation and migration of B16F10 cells in response to serum stimulation (Fig. 6B) . This result indicates that the function of Prx2 in melanoma cells is perhaps independent of oncogenic BRAF mutation.
For in vivo experiment, we used the siRNA-mediated knockdown of the Prx2 expression that guaranteed a stable depletion of the Prx2 expression during lung metastasis assay (Fig. 6C) .
Then, the B16F10 cells transfected with the mPrx2 siRNA were injected into mice through the tail vein. After 10 days, the mouse lungs were isolated and examined for metastasized tumor nodules. Microscopic examination of both the lung surface and the HE-stained tissue sections showed that the B16F10 cells with Prx2 knockdown invaded and colonized in lungs more aggressively than did control cells ( Fig. 6D and E) .
A fungal product, gliotoxin, inhibits in vitro migration and in vivo lung metastasis of melanoma cells
Since a fungal secondary metabolite called gliotoxin (GT) was shown to be the first natural compound that exhibits the thioredoxin-dependent peroxidase activity representing a typical Prx activity (29), we tested a therapeutic potential of GT for prevention of melanoma metastasis. Indeed, the GT treatment reduced the basal level of intracellular H 2 O 2 in the Prx2-lacking SK28 cells at the non-toxic level ( Supplementary Fig. S5 and Fig. 7A ), which verifies the GT's peroxidase activity. Once again, the GT treatment reduced the Src/ERK activation 
and the β-catenin phosphorylation, but it increased the E-cadherin expression in SK28 cells (Fig. 7B) . Furthermore, GT reduced the proliferation and migration of both SK5 and SK28 cells in response to serum stimulation (Fig. 7C and D) . This result indicates that the GT acts as a small-molecule substitute for Prx2 in melanoma cells. To examine the therapeutic efficacy in vivo, the GT was intraperitoneally injected into the mice following the injection of B16F10 cells. The GT treatment evidently reduced lung metastasis of melanoma cells (Fig.   7E ). In addition, GT more drastically reduced the lung metastasis of B16F10 cells in which Prx2 had been knocked down (Fig. 7F ). This result reveals the therapeutic potential of a small molecule substituting for Prx2 as an inhibitor of melanoma metastasis. 
Discussion
Advanced malignant tumors usually accompanies with aggressive metastasis. Since the metastatic tumor cells are refractory to the existing chemotherapies, the tumors metastasized to the multiple sites are often fatal. Likewise, the metastatic malignancy is the main reason for melanoma being a deadly skin cancer. Unless metastasized to the lymph node or distant sites, the melanoma lesion can be cleaned by a surgical resection. The tumor metastasis is actually a complex and multi-step process where tumor cells with metastatic potential 1) escape from primary site, 2) circulate through blood and lymphatic vessels, 3) extravasate to distant secondary organs, and 4) finally adapt to the new microenvironment. Therefore, it is difficult to develop an anti-metastatic therapeutic that is powerful by itself or useful in combination with preexisting medications. In this study, we show for the first time that among endogenous antioxidant enzymes the Prx2 specifically down-regulates proliferation and migration of melanoma cells in vitro and suppresses their lung metastasis in vivo. The striking mechanism involved is that the Prx2 expression reduced the ERK and Src activation, which in turn resulted in a marked increase of the E-cadherin/β-catenin complexes in the adherens junctions (Fig. 7G) . of Prx1 is transcriptionally regulated by oxidative stress-sensitive Nrf2 transcription factor in cancer cells (38). Thus, the role of Prx1 in cancer cells is supposedly to serve as an antioxidant defense against oxidative stress. In contrast, the Prx2 knockout mice did not show any phenotypes relevant to cancer (39), and the Prx2 expression was relatively low in melanoma and skin cancer versus other cancer types (www.proteinatlas.org). Indeed, it recently determined that the Prx2 expression is silenced in melanoma and acute myeloid leukemia by the hypermethylation of the CpG islands in the promoter region and epigenetically by histone H3 acetylation (17, 40). Our study now reveals that silencing of the Prx2 expression in melanoma cells results in the accumulation of intracellular H 2 O 2 , which in turn leads to the disruption of E-cadherin/β-catenin complexes in adherens junctions by Src/ERK pathways. Moreover, we show that such disrupted junctions lead to an increase in the melanoma cell migration and metastasis (Fig. 7G) . Accordingly, the specific silencing of Prx2 and subsequent increase in intracellular ROS level is likely a prerequisite for metastasis of melanoma tumor. Interestingly, there have been supportive documents that ROS promotes tumor metastasis (41, 42) and that Prx2 is involved in cell adhesion by stabilizing Ecadherin/β-catenin complexes (43). Hence, the Prx2 can be a novel metastasis suppressor that induces the stabilization of adherens junctions.
The oncogenic BRAF mutation is predominant in malignant melanoma (44) and leads to the constitutive ERK activation (45). However, our data clearly indicate that the Prx2-dependent regulation of melanoma cell function is regardless of the BRAF mutation because Prx2 regulated the serum-induced ERK activation in both human melanoma cell lines with active BRAF mutation and B16F10 melanoma cells with wild-type BRAF. We actually performed additional control experiments to concrete this proposal. To discriminate the wild-type and oncogenic BRAF, we used a BRAF inhibitor PLX4720 specific to the constitutively-active oncogenic mutant (BRAF-V600E). When the effect of this inhibitor on ERK activation was compared with the MEK inhibitor PD98056, the PLX4720 inhibited only the basal, but not the seruminduced, ERK phosphorylation; whereas, the PD98059 inhibited both the basal and serum-induced ERK activation ( Supplementary Fig. S4A and S4D) . Furthermore, the PLX4720 had no effect on the serum-induced Src/ERK activation enhanced by Prx2 silencing in G361 cells (Supplementary Fig.   S4E ). This evidence support that the Prx2 effect is independent of BRAF-V600E mutant and the Prx2-dependent H 2 O 2 is thought to be involved in the redox-dependent ERK activation at the The cells were transfected with control or isoform-specific siRNAs as indicated for 24 hrs.
The experiments were repeated three times (*P<0.01; **P<0.005; N.S., not significant). 
